Kiniksa (KNSA) shifts from survival to growth as Arcalyst nears blockbuster sales and pipeline KPL-387 readouts loom—get the ...

This week's report explores the pharmaceutical industry’s evolution toward resilient, scalable systems that prioritize ...

NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...

As cancer cases climb steadily across India, lower-cost biosimilars like Tishtha could reshape access to life-saving ...

In the treatment of inflammatory bowel disease, synthetic mucus gels can be used to deliver monoclonal antibodies without inducing broad immunosuppression.

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)Nantes, France, January 21, 2026 – 6pm CET - OSE ...

Proposed Operation Warp Speed for Alzheimer’s: an acceleration fund to fast-track cures and slash trillion-dollar costs.

With RSV cases on the rise, an Annenberg survey finds most Americans would be likely to recommend the RSV vaccine to older adults and pregnant people and the monoclonal antibody injection for infants.

Novartis received breakthrough therapy designation from the FDA for ianalumab, a monoclonal antibody aimed at treating Sjögren’s disease. Ianalumab works by depleting B cells and blocking BAFF-R ...